Sandoz signs deal for antifungal from Astellas in buff-up of anti-infectives portfolio
Generics giant and Novartis division Sandoz signed a deal with Astellas for worldwide rights to the antifungal drug micafungin sodium, also known as Mycamine.
Sandoz and Astellas put out word Tuesday that the deal has been signed, with a tentative closing date sometime in the first half of the year. Astellas said in a statement that Sandoz is paying between $62.5 million and $75 million upfront — dependent on when the deal actually closes — with potential for milestone payments based on sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.